AR132030A2 - Proceso de producción de formas cristalinas de derivado de diazabiciclooctano - Google Patents

Proceso de producción de formas cristalinas de derivado de diazabiciclooctano

Info

Publication number
AR132030A2
AR132030A2 ARP240100517A ARP240100517A AR132030A2 AR 132030 A2 AR132030 A2 AR 132030A2 AR P240100517 A ARP240100517 A AR P240100517A AR P240100517 A ARP240100517 A AR P240100517A AR 132030 A2 AR132030 A2 AR 132030A2
Authority
AR
Argentina
Prior art keywords
vii
compound represented
formula
heterocyclyl
alkyl
Prior art date
Application number
ARP240100517A
Other languages
English (en)
Inventor
Takao Abe
Takeshi Furuuchi
Yoshiaki Sakamaki
Nakako Mitsuhashi
Yumiko Saito
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Publication of AR132030A2 publication Critical patent/AR132030A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Un proceso para producir formas cristalinas I - IV de un compuesto representado por la fórmula (VII-1). Reivindicación 1: Un proceso para producir un compuesto representado por la fórmula (VII), caracterizado porque comprende: alternativamente añadir un compuesto crudo representado por la siguiente fórmula (VII-CR) y un tampón helado para obtener una solución que tiene un pH de 4 a 5,5, concentrar después de desalar con un adsorbente sintético de ser necesario, ajustar la temperatura, sembrar de ser necesario y cristalizar por adición de un solvente pobre a base de alcohol para producir el compuesto representado por la fórmula (VII) (en cada una de las fórmulas anteriores, R³ es alquilo C₁₋₆ o heterociclilo, R³ se puede modificar con 0 a 5 R⁴, R⁴ se puede sustituir consecutivamente, aquí, R⁴ es alquilo C₁₋₆, heterociclilo, R⁵(R⁶)N- o un grupo protector, R⁵ y R⁶ son cada uno, de modo independiente, hidrógeno o alquilo C₁₋₆ o juntos forman un heterociclilo. Por otra parte, R³, R⁵ y R⁶ se pueden someter a cierre del anillo en una posición arbitraria).
ARP240100517A 2013-10-08 2024-03-01 Proceso de producción de formas cristalinas de derivado de diazabiciclooctano AR132030A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013211242 2013-10-08

Publications (1)

Publication Number Publication Date
AR132030A2 true AR132030A2 (es) 2025-05-21

Family

ID=52813113

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP140103759A AR097971A1 (es) 2013-10-08 2014-10-08 Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas
ARP240100515A AR132028A2 (es) 2013-10-08 2024-03-01 Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida
ARP240100516A AR132029A2 (es) 2013-10-08 2024-03-01 Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida
ARP240100517A AR132030A2 (es) 2013-10-08 2024-03-01 Proceso de producción de formas cristalinas de derivado de diazabiciclooctano

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ARP140103759A AR097971A1 (es) 2013-10-08 2014-10-08 Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas
ARP240100515A AR132028A2 (es) 2013-10-08 2024-03-01 Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida
ARP240100516A AR132029A2 (es) 2013-10-08 2024-03-01 Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida

Country Status (22)

Country Link
US (5) US10131665B2 (es)
EP (4) EP3613740A1 (es)
JP (3) JP6617029B2 (es)
KR (2) KR102487297B1 (es)
CN (2) CN105612159A (es)
AR (4) AR097971A1 (es)
AU (1) AU2014332960B2 (es)
BR (2) BR122022016622B1 (es)
CA (2) CA2926071C (es)
DK (1) DK3067355T3 (es)
ES (2) ES2901198T3 (es)
HK (1) HK1219479A1 (es)
HU (1) HUE051925T2 (es)
IL (2) IL244969B (es)
MX (2) MX361659B (es)
MY (1) MY199066A (es)
NZ (5) NZ757222A (es)
RU (1) RU2695219C2 (es)
SG (1) SG11201602723RA (es)
TW (1) TWI673269B (es)
WO (1) WO2015053297A1 (es)
ZA (1) ZA201602054B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR091222A1 (es) * 2012-05-30 2015-01-21 Meiji Seika Pharma Co Ltd INHIBIDOR DE b-LACTAMASA Y PROCESO PARA PREPARARLO
KR102239725B1 (ko) 2013-09-24 2021-04-12 메이지 세이카 파루마 가부시키가이샤 디아자비시클로옥탄 유도체의 제조법과 그의 중간체
MY199066A (en) 2013-10-08 2023-10-12 Meiji Seika Pharma Co Ltd Processes for producing diazabicyclooctane compounds
BR112017010445B8 (pt) * 2014-12-05 2024-02-27 Meiji Seika Pharma Co Ltd Processo de produção de cristais de derivado de diazabiciclo-octano e preparação liofilizada estável
US10208041B2 (en) * 2016-10-07 2019-02-19 Hoffman-La Roche Inc. Diazabicyclooctane compounds
CN110446708B (zh) 2017-07-21 2022-12-02 安塔比奥公司 化学化合物
WO2019064065A1 (en) 2017-09-27 2019-04-04 F. Hoffmann-La Roche Ag PHARMACEUTICAL FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
WO2019064066A1 (en) 2017-09-27 2019-04-04 F. Hoffmann-La Roche Ag PHARMACEUTICAL FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
WO2019064071A1 (en) 2017-09-27 2019-04-04 F. Hoffmann-La Roche Ag CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
CN107941944B (zh) * 2017-11-23 2020-09-15 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法
CN107991404B (zh) * 2017-11-23 2021-01-08 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酰胺的检测方法
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
EP3854786B1 (en) * 2018-09-21 2026-02-18 UBE Corporation Method for producing amino acid derivatives
JP7096958B2 (ja) * 2020-07-13 2022-07-06 日本碍子株式会社 精製方法
CN113552250A (zh) * 2021-06-30 2021-10-26 海南海灵化学制药有限公司 一种盐酸头孢唑兰的杂质检测方法
WO2024263708A2 (en) * 2023-06-23 2024-12-26 Board Of Trustees Of Michigan State University Ornithine decarboxylase (odc) inhibitors and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5038509B1 (es) 1970-10-21 1975-12-10
GB1589317A (en) 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS6019759B2 (ja) 1977-11-24 1985-05-17 イ−ライ・リリ−・アンド・カンパニ− 非経口投予用11115152139199東京都中央区京橋2丁目3番13号
JPS60255723A (ja) 1984-05-31 1985-12-17 Ono Pharmaceut Co Ltd メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
JPH07117533B2 (ja) 1985-08-28 1995-12-18 株式会社生体科学研究所 トランスフエリンおよびその用途
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
TW264475B (es) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
EP0758651B1 (en) 1994-05-02 2002-09-11 Shionogi & Co., Ltd. Crystal of pyrrolidylthiocarbapenem derivative, lyophilized preparation containing said crystal, and process for producing the same
JP2843444B2 (ja) 1994-05-02 1999-01-06 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の結晶,該結晶を含む凍結乾燥製剤,およびその製造方法
DE19531874C1 (de) 1995-08-30 1996-10-02 Daimler Benz Ag Seitenwandbaugruppe für eine Kraftfahrzeugkarosserie
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
MY162532A (en) 2008-01-18 2017-06-15 Merck Sharp & Dohme Beta-lactamase inhibitors
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
WO2010126820A2 (en) 2009-04-30 2010-11-04 Merck Sharp & Dohme Corp. Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
JP2012122603A (ja) 2010-11-15 2012-06-28 Nifco Inc コネクタ装置
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
CN103328476B (zh) 2010-12-22 2016-12-28 明治制果药业株式会社 光学活性二氮杂环辛烷衍生物及其制备方法
US8829191B2 (en) 2011-06-17 2014-09-09 Melanie Simone Ronsheim Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
KR101512738B1 (ko) 2011-08-27 2015-04-17 욱크하르트 리미티드 1,6-디아자-비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
KR101618424B1 (ko) 2011-08-30 2016-05-04 욱크하르트 리미티드 1,6-디아자비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
BR112014003476A2 (pt) 2011-09-13 2017-03-01 Wockhardt Ltd compostos contendo nitrogênio e seu uso
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
AR091222A1 (es) 2012-05-30 2015-01-21 Meiji Seika Pharma Co Ltd INHIBIDOR DE b-LACTAMASA Y PROCESO PARA PREPARARLO
CA2881169C (en) * 2012-08-25 2020-06-16 Wockhardt Limited 1,6-diazabicyclo [3,2,1]octan - 7 - one derivatives and their use in the treatment of bacterial infections
KR102239725B1 (ko) 2013-09-24 2021-04-12 메이지 세이카 파루마 가부시키가이샤 디아자비시클로옥탄 유도체의 제조법과 그의 중간체
MY199066A (en) 2013-10-08 2023-10-12 Meiji Seika Pharma Co Ltd Processes for producing diazabicyclooctane compounds
US9688677B1 (en) 2014-03-29 2017-06-27 Wockhardt Limited Process for preparation of sodium (2S, 5R)-6-(benzyloxy)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxylate
BR112017010445B8 (pt) 2014-12-05 2024-02-27 Meiji Seika Pharma Co Ltd Processo de produção de cristais de derivado de diazabiciclo-octano e preparação liofilizada estável

Also Published As

Publication number Publication date
US20160272641A1 (en) 2016-09-22
NZ719568A (en) 2018-06-29
NZ743374A (en) 2021-12-24
CA3110803A1 (en) 2015-04-16
BR122022016622B1 (pt) 2023-11-07
US12221443B2 (en) 2025-02-11
JP6995810B2 (ja) 2022-01-17
HUE051925T2 (hu) 2021-04-28
MX2016004506A (es) 2016-06-16
NZ757221A (en) 2021-12-24
EP3299370A1 (en) 2018-03-28
US20220348578A1 (en) 2022-11-03
IL289275B (en) 2022-10-01
MX361659B (es) 2018-12-13
EP3067355A1 (en) 2016-09-14
US11414417B2 (en) 2022-08-16
JP2021193107A (ja) 2021-12-23
EP3613740A1 (en) 2020-02-26
CN105612159A (zh) 2016-05-25
NZ757222A (en) 2021-12-24
EP3067355B1 (en) 2020-12-16
EP3067355A4 (en) 2017-04-26
MY199066A (en) 2023-10-12
AR097971A1 (es) 2016-04-20
JPWO2015053297A1 (ja) 2017-03-09
US20190031659A1 (en) 2019-01-31
US10604522B2 (en) 2020-03-31
ZA201602054B (en) 2019-06-26
AR132029A2 (es) 2025-05-21
TW201605855A (zh) 2016-02-16
RU2016116501A (ru) 2017-11-15
WO2015053297A1 (ja) 2015-04-16
KR102388529B1 (ko) 2022-04-20
JP6617029B2 (ja) 2019-12-04
HK1219479A1 (zh) 2017-04-07
AU2014332960B2 (en) 2018-03-29
AU2014332960A1 (en) 2016-05-26
BR112016006266A2 (es) 2017-08-22
HK1250030A1 (en) 2018-11-23
ES2901198T3 (es) 2022-03-21
MX383661B (es) 2025-03-14
CA2926071C (en) 2021-11-09
TWI673269B (zh) 2019-10-01
RU2019115119A (ru) 2019-05-29
IL289275A (en) 2022-02-01
EP3299370B1 (en) 2021-11-24
KR102487297B1 (ko) 2023-01-12
RU2695219C2 (ru) 2019-07-22
NZ757220A (en) 2021-12-24
KR20220054694A (ko) 2022-05-03
CA3110803C (en) 2022-09-27
IL244969A0 (en) 2016-05-31
RU2019115119A3 (es) 2022-04-26
JP7182677B2 (ja) 2022-12-02
JP2020007366A (ja) 2020-01-16
AR132028A2 (es) 2025-05-21
US20250059191A1 (en) 2025-02-20
IL289275B2 (en) 2023-02-01
EP3613741A1 (en) 2020-02-26
US10131665B2 (en) 2018-11-20
DK3067355T3 (da) 2021-01-04
KR20160065871A (ko) 2016-06-09
CA2926071A1 (en) 2015-04-16
ES2842225T3 (es) 2021-07-13
BR112016006266B1 (pt) 2022-11-16
RU2016116501A3 (es) 2018-07-12
SG11201602723RA (en) 2016-05-30
US20200181143A1 (en) 2020-06-11
IL244969B (en) 2022-01-01
CN111153903A (zh) 2020-05-15

Similar Documents

Publication Publication Date Title
AR132029A2 (es) Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida
AR123048A2 (es) Moduladores de p2x7
AR108812A1 (es) Proceso para preparar un derivado de piridona policíclica sustituida y cristal del mismo
CR20140238A (es) Derivados nucleósidos con sustitución 2´, 4´- difluoro-2´-metilo como inhibidores de la replicación del arn del vhc
CL2017001377A1 (es) Una nueva forma cristalina de un derivado de bencimidazol y un método de preparación de los mismos
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
AR103561A1 (es) Fenilpiridinas herbicidas
ES2869172T3 (es) Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro
CU24411B1 (es) Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos
MX2016004964A (es) Compuesto heterociclico fusionado, metodo de preparacion del mismo, composicion farmaceutica, y usos del mismo.
MX2016001304A (es) Polimorfo de inhibidores de syk.
AR096238A1 (es) Proceso para preparar derivados de 3-((2s,5s)-4-metilen-5-(3-oxopropil)tetrahidrofuran-2-il)propanol e intermediarios útiles para el mismo
MX2017000330A (es) Derivado de piridona que tiene un grupo tetrahidropiranilmetilo.
AR099138A1 (es) Piridinas fusionadas como inhibidores del complejo p97
AR133154A2 (es) Proceso de producción de cristales de derivado de diazabiciclooctano y preparación liofilizada estable
CU20160004A7 (es) Bencil-1 h-pirazolo[3,4-b]piridinas
AR098492A1 (es) Derivados de purina
AR098200A1 (es) Proceso para preparar aluminoxanos, componente catalizador y aluminoxano resultantes
MX2016003892A (es) Uso de dihidrooxindolilsulfonamidas sustituidas, o sus sales, para aumentar la tolerancia de plantas al estres.
AR097435A1 (es) 6-alquinilpiridinas
MX388969B (es) Formulas cristalinas de grapiprant.
MX394744B (es) Produccion microbiana de aminas grasas
MX2019005254A (es) Proceso para la purificacion de pirazolpiridazinas.
AR098070A1 (es) Compuesto bicíclico que contiene azufre
PH12018500301A1 (en) Substituted 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one antibacterials